Autoantibody-mediated complement c3a receptor activation contributes to the pathogenesis of preeclampsia

Hypertension

Volumn 60, Issue 3, 2012, Pages 712-721

  Wang, Wei ^a,b,c   Irani, Roxanna A ^b,c   Zhang, Yujin ^b,c   Ramin, Susan M ^b   Blackwell, Sean C ^b   Tao, Lijian ^a   Kellems, Rodney E ^b,c   Xia, Yang ^b,c  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

AT 1 receptor; autoantibody; C3a receptor; complement C3a; hypertension; placenta; preeclampsia

Indexed keywords

ALBUMIN; ANGIOTENSIN 1 RECEPTOR; AUTOANTIBODY; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C3A RECEPTOR; COMPLEMENT RECEPTOR; CREATININE; IMMUNOGLOBULIN G; MATERNAL ANTIBODY; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 1;

ADULT; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT DEPOSITION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; HYPERTENSION; IN VIVO STUDY; INTRAUTERINE GROWTH RETARDATION; KIDNEY; MOUSE; NONHUMAN; PATHOGENESIS; PLACENTA; PREECLAMPSIA; PRIORITY JOURNAL; PROTEINURIA; SIGNAL TRANSDUCTION;

ADULT; ANIMALS; AUTOANTIBODIES; CASE-CONTROL STUDIES; CHORIONIC VILLI; COMPLEMENT C3; FEMALE; HUMANS; HYPERTENSION; KIDNEY; MICE; MICE, INBRED C57BL; MODELS, ANIMAL; PLACENTA; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY, ANIMAL; PROTEINURIA; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, COMPLEMENT; TISSUE CULTURE TECHNIQUES; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84865480216     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.112.191817     Document Type: Article

References (54)

1. Redman CW, Sargent IL. Preeclampsia and the systemic inflammatory response. Semin Nephrol. 2004;24:565-570.
2. Wallukat G, Homuth V, Fischer T, Lindschau C, Horstkamp B, Jupner A, Baur E, Nissen E, Vetter K, Neichel D, Dudenhausen JW, Haller H, Luft FC. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin at1 receptor. J Clin Invest. 1999;103:945-952.
3. Xia Y, Zhou CC, Ramin SM, Kellems RE. Angiotensin receptors, autoimmunity, and preeclampsia. J Immunol. 2007;179:3391-3395.
4. Xia Y, Kellems RE. Receptor-activating autoantibodies and disease: Preeclampsia and beyond. Expert Rev Clin Immunol. 2011;7:659-674.
5. LaMarca B. Progress toward identifying potential markers for preeclampsia: role of agonistic autoantibody to the angiotensin II type I receptor. Hypertension. 2011;55:236-237.
6. Irani RA, Xia Y. Renin angiotensin signaling in normal pregnancy and preeclampsia. Semin Nephrol. 2010;31:47-58.
7. Irani RA, Xia Y. The functional role of the renin-angiotensin system in pregnancy and preeclampsia. Placenta. 2008;29:763-771.
8. Xia Y, Wen H, Bobst S, Day MC, Kellems RE. Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human trophoblast cells. J Soc Gynecol Investig. 2003;10:82-93.
9. + mobilization through angiotensin receptor activation. Circulation. 2004;110:1612-1619.
10. Dechend R, Homuth V, Wallukat G, Kreuzer J, Park JK, Theuer J, Juepner A, Gulba DC, Mackman N, Haller H, Luft FC. At(1) receptor agonistic antibodies from preeclamptic patients cause vascular cells to express tissue factor. Circulation. 2000;101:2382-2387.
11. Dechend R, Gratze P, Wallukat G, Shagdarsuren E, Plehm R, Brasen JH, Fiebeler A, Schneider W, Caluwaerts S, Vercruysse L, Pijnenborg R, Luft FC, Muller DN. Agonistic autoantibodies to the at1 receptor in a transgenic rat model of preeclampsia. Hypertension. 2005;45:742-746.
12. Bobst SM, Day MC, Gilstrap LC III, Xia Y, Kellems RE. Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human mesangial cells and induce interleukin-6 and plasminogen activator inhibitor-1 secretion. Am J Hypertens. 2005;18:330-336.
13. Zhou CC, Irani RA, Zhang Y, Blackwell SC, Mi T, Wen J, Shelat H, Geng YJ, Ramin SM, Kellems RE, Xia Y. Angiotensin receptor agonistic autoantibody-mediated tumor necrosis factor-α induction contributes to increased soluble endoglin production in preeclampsia. Circulation. 2011;121:436-444.
14. Zhou CC, Zhang Y, Irani RA, Zhang H, Mi T, Popek EJ, Hicks MJ, Ramin SM, Kellems RE, Xia Y. Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice. Nat Med. 2008;14: 855-862.
15. Wenzel K, Rajakumar A, Haase H, Geusens N, Hubner N, Schulz H, Brewer J, Roberts L, Hubel CA, Herse F, Hering L, Qadri F, Lindschau C, Wallukat G, Pijnenborg R, Heidecke H, Riemekasten G, Luft FC, Muller DN, Lamarca B, Dechend R. Angiotensin II type 1 receptor antibodies and increased angiotensin II sensitivity in pregnant rats. Hypertension. 2011;58:77-84.
16. Parrish MR, Wallace K, Tam Tam KB, Herse F, Weimer A, Wenzel K, Wallukat G, Ray LF, Arany M, Cockrell K, Martin JN, Dechend R, LaMarca B. Hypertension in response to AT1-AA: role of reactive oxygen species in pregnancy-induced hypertension. Am J Hypertens. 2011;24:835-840.
17. Parrish MR, Ryan MJ, Glover P, Brewer J, Ray L, Dechend R, Martin JN, Martin JN, Lamarca BB. Angiotensin II type 1 autoantibody induced hypertension during pregnancy is associated with renal endothelial dysfunction. Gend Med. 2011;8:184-188.
18. Siddiqui AH, Irani RA, Blackwell SC, Ramin SM, Kellems RE, Xia Y. Angiotensin receptor agonistic autoantibody is highly prevalent in preeclampsia: correlation with disease severity. Hypertension. 2010;55: 386-393.
19. Herse F, Verlohren S, Wenzel K, Pape J, Muller DN, Modrow S, Wallukat G, Luft FC, Redman CW, Dechend R. Prevalence of agonistic autoantibodies against the angiotensin II type 1 receptor and soluble fms-like tyrosine kinase 1 in a gestational age-matched case study. Hypertension. 2009;53:393-398.
20. Holers VM. The spectrum of complement alternative pathway-mediated diseases. Immunol Rev. 2008;223:300-316.
21. Walport MJ. Complement: first of two parts. N Engl J Med. 2001;344: 1058-1066.
22. Sjoberg AP, Trouw LA, Blom AM. Complement activation and inhibition: a delicate balance. Trends Immunol. 2009;30:83-90.
23. Sacks SH. Complement fragments c3a and c5a: the salt and pepper of the immune response. Eur J Immunol. 2010;40:668-670.
24. Hutamekalin P, Takeda K, Tani M, Tsuga Y, Ogawa N, Mizutani N, Yoshino S. Effect of the c3a-receptor antagonist sb 290157 on anti-ova polyclonal antibody-induced arthritis. J Pharmacol Sci. 2010;112:56-63.
25. Ames RS, Lee D, Foley JJ, Jurewicz AJ, Tornetta MA, Bautsch W, Settmacher B, Klos A, Erhard KF, Cousins RD, Sulpizio AC, Hieble JP, McCafferty G, Ward KW, Adams JL, Bondinell WE, Underwood DC, Osborn RR, Badger AM, Sarau HM. Identification of a selective nonpeptide antagonist of the anaphylatoxin c3a receptor that demonstrates antiinflammatory activity in animal models. J Immunol. 2001;166: 6341-6348.
26. Jacob A, Bao L, Brorson J, Quigg RJ, Alexander JJ. C3AR inhibition reduces neurodegeneration in experimental lupus. Lupus. 2010;19:73-82.
27. Saito S, Shiozaki A, Nakashima A, Sakai M, Sasaki Y. The role of the immune system in preeclampsia. Mol Aspects Med. 2007;28:192-209.
28. Fang CJ, Richards A, Liszewski MK, Kavanagh D, Atkinson JP. Advances in understanding of pathogenesis of ahus and hellp. Br J Haematol. 2008;143:336-348.
29. Girardi G, Yarilin D, Thurman JM, Holers VM, Salmon JE. Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. J Exp Med. 2006;203:2165-2175.
30. Girardi G, Bulla R, Salmon JE, Tedesco F. The complement system in the pathophysiology of pregnancy. Mol Immunol. 2006;43:68-77.
31. Salmon JE, Girardi G. Antiphospholipid antibodies and pregnancy loss: a disorder of inflammation. J Reprod Immunol. 2008;77:51-56.
32. Lynch AM, Gibbs RS, Murphy JR, Byers T, Neville MC, Giclas PC, Salmon JE, Van Hecke TM, Holers VM. Complement activation fragment BB in early pregnancy and spontaneous preterm birth. Am J Obstet Gynecol. 2008;199:354, e351-e358.
33. Cohen D, Buurma A, Goemaere NN, Girardi G, le Cessie S, Scherjon S, Bloemenkamp KW, de Heer E, Bruijn JA, Bajema IM. Classical complement activation as a footprint for murine and human antiphospholipid antibody-induced fetal loss. J Pathol. 2011;225:502-511.
34. Lynch AM, Gibbs RS, Murphy JR, Giclas PC, Salmon JE, Holers VM. Early elevations of the complement activation fragment c3a and adverse pregnancy outcomes. Obstet Gynecol. 2011;117:75-83.
35. Derzsy Z, Prohaszka Z, Rigo J Jr, Fust G, Molvarec A. Activation of the complement system in normal pregnancy and preeclampsia. Mol Immunol. 2010;47:1500-1506.
36. Roberts JM, Pearson G, Cutler J, Lindheimer M. Summary of the nhlbi working group on research on hypertension during pregnancy. Hypertension. 2003;41:437-445.
37. Irani RA, Zhang Y, Blackwell SC, Zhou CC, Ramin SM, Kellems RE, Xia Y. The detrimental role of angiotensin receptor agonistic autoanti-bodies in intrauterine growth restriction seen in preeclampsia. J Exp Med. 2009;206:2809-2822.
38. Dechend R, Viedt C, Muller DN, Ugele B, Brandes RP, Wallukat G, Park JK, Janke J, Barta P, Theuer J, Fiebeler A, Homuth V, Dietz R, Haller H, Kreuzer J, Luft FC. AT1 receptor agonistic antibodies from preeclamptic patients stimulate nadph oxidase. Circulation. 2003;107:1632-1639.
39. Irani RA, Zhang Y, Zhou CC, Blackwell SC, Hicks MJ, Ramin SM, Kellems RE, Xia Y. Autoantibody-mediated angiotensin receptor activation contributes to preeclampsia through tumor necrosis factor-α signaling. Hypertension. 2010;55:1246-1253.
40. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA. Excess placental soluble fms-like tyrosine kinase 1 (sflt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111:649-658.
41. Pratt JR, Basheer SA, Sacks SH. Local synthesis of complement component c3 regulates acute renal transplant rejection. Nat Med. 2002;8: 582-587.
42. Lin ZH, Fukuda N, Jin XQ, Yao EH, Ueno T, Endo M, Saito S, Matsumoto K, Mugishima H. Complement 3 is involved in the synthetic phenotype and exaggerated growth of vascular smooth muscle cells from spontaneously hypertensive rats. Hypertension. 2004;44:42-47.
43. Shagdarsuren E, Wellner M, Braesen JH, Park JK, Fiebeler A, Henke N, Dechend R, Gratze P, Luft FC, Muller DN. Complement activation in angiotensin II-induced organ damage. Circ Res. 2005;97:716-724.
44. Rampersad R, Barton A, Sadovsky Y, Nelson DM. The c5b-9 membrane attack complex of complement activation localizes to villous trophoblast injury in vivo and modulates human trophoblast function in vitro. Placenta. 2008;29:855-861.
45. Busche MN, Pavlov V, Takahashi K, Stahl GL. Myocardial ischemia and reperfusion injury is dependent on both igm and mannose-binding lectin. Am J Physiol. 2009;297:H1853-H1859.
46. Bao L, Wang Y, Haas M, Quigg RJ. Distinct roles for c3a and c5a in complement-induced tubulointerstitial injury. Kidney Int. 2011;80: 524-534.
47. Rynkowski MA, Kim GH, Garrett MC, Zacharia BE, Otten ML, Sosunov SA, Komotar RJ, Hassid BG, Ducruet AF, Lambris JD, Connolly ES. C3a receptor antagonist attenuates brain injury after intracerebral hemorrhage. J Cereb Blood Flow Metab. 2009;29:98-107.
48. Holers VM, Girardi G, Mo L, Guthridge JM, Molina H, Pierangeli SS, Espinola R, Xiaowei LE, Mao D, Vialpando CG, Salmon JE. Complement c3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med. 2002;195:211-220.
49. Girardi G, Prohaszka Z, Bulla R, Tedesco F, Scherjon S. Complement activation in animal and human pregnancies as a model for immunological recognition. Mol Immunol. 2011;48:1621-1630.
50. Qing X, Redecha PB, Burmeister MA, Tomlinson S, D'Agati VD, Davisson RL, Salmon JE. Targeted inhibition of complement activation prevents features of preeclampsia in mice. Kidney Int. 2010;79:331-339.
51. Singh J, Ahmed A, Girardi G. Role of complement component c1q in the onset of preeclampsia in mice. Hypertension. 2011;58:716-724.
52. Siddiqui AH, Irani RA, Zhang Y, Dai Y, Blackwell SC, Ramin SM, Kellems RE, Xia Y. Recombinant vascular endothelial growth factor 121 attenuates autoantibody-induced features of pre-eclampsia in pregnant mice. Am J Hypertens. 2011;24:606-612.
53. Zhou CC, Ahmad S, Mi T, Abbasi S, Xia L, Day MC, Ramin SM, Ahmed A, Kellems RE, Xia Y. Autoantibody from women with preeclampsia induces soluble fms-like tyrosine kinase-1 production via angiotensin type 1 receptor and calcineurin/nuclear factor of activated t-cells signaling. Hypertension. 2008;51:1010-1019.
54. Zhou CC, Irani RA, Dai Y, Blackwell SC, Hicks MJ, Ramin SM, Kellems RE, Xia Y. Autoantibody-mediated IL-6-dependent endothelin-1 elevation underlies pathogenesis in a mouse model of preeclampsia. J Immunol. 2011; 186:6024-6034.